Subjective cognitive decline is a better marker for future cognitive decline in females than in males

• Published in: Alzheimer's research & therapy 2022-12, Vol.14 (1), p.197-197, Article 197
• Main Authors: Oliver, Michael D, Morrison, Cassandra, Kamal, Farooq, Graham, Jillian, Dadar, Mahsa
• Format: Article
• Language: English
• Subjects: Aged; Alzheimer Disease - psychology; Alzheimer's disease; Biomarkers; Cognition - physiology; Cognitive change; Cognitive Dysfunction - diagnosis; Demographic aspects; Development and progression; Female; Humans; Male; Neurological research; Neuropsychological Tests; Risk factors; Sex disparities; Sex factors in disease; Subjective cognitive decline
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-022-01138-w

The identification of biomarkers for early detection of Alzheimer's disease (AD) is critical to the development of therapies and interventions targeted at symptom management and tracking the pathophysiology of disease. The endorsement of subjective cognitive decline (SCD) has emerged as a potential indicator of early change in cognitive status that may be predictive of future impairment at a time when measurable declines in neuropsychological performance cannot be detected. While there are numerous findings revealing sex differences in the prevalence of AD, there is a paucity of research examining sex differences in SCD. Therefore, the goal of this project was to determine if the relationship between the endorsement of SCD and future cognitive changes differ as a function of biological sex. A sample of 3019 male and female healthy older adults (2188 without SCD, 831 with SCD), with a mean follow-up time of 5.7 years, were included from the Rush Alzheimer's Disease Center Research Sharing Hub. Linear regressions were performed to determine group differences in baseline cognitive scores, while linear mixed-effects models were completed to determine group differences in the rate of cognitive change over time. Individuals endorsing SCD had significantly lower baseline cognitive scores and increased rates of decline in all cognitive domains compared to those without SCD. Males exhibited significantly lower scores in baseline performance in global cognition, episodic memory, and perceptual speed regardless of SCD classification. Females with SCD were found to decline at significantly faster rates than both males with SCD and males and females without SCD in all cognitive domains over a maximum 15-year follow-up period. SCD is related to lower baseline cognitive performance and faster cognitive decline compared to those who do not endorse SCD. Females with SCD have the fastest rate of decline suggesting that SCD may be more predictive of future decline in females than in males. Targeted assessments of SCD may allow for the identification of individuals for inclusion in intervention trials, and other research studies, aiming to attenuate casual disease processes, which may ultimately aid in the mitigation of sex disparities in AD.